PMC:7784786 / 441-713
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 25 | 77-82 | Gene | denotes | IFN-γ | Gene:3458 |
| 26 | 84-88 | Gene | denotes | IL-6 | Gene:3569 |
| 27 | 93-98 | Gene | denotes | TNF-α | Gene:7124 |
| 30 | 172-180 | Species | denotes | patients | Tax:9606 |
| 34 | 194-204 | Chemical | denotes | itolizumab | MESH:C000597346 |
| 35 | 245-255 | Chemical | denotes | Itolizumab | MESH:C000597346 |
| 38 | 148-162 | Disease | denotes | critically ill | MESH:D016638 |
| 39 | 163-171 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T7 | 100-244 | Sentence | denotes | Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. |